Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
8 studies found for:    FC-6 and colorectal cancer
Show Display Options
Rank Status Study
1 Active, not recruiting A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
Condition: Metastatic Colorectal Cancer
Interventions: Biological: cetuximab;   Drug: 5-FU;   Drug: oxaliplatin;   Drug: leucovorin
2 Not yet recruiting Safety and Effectiveness Study of Chemotherapy and Ziv-aflibercept to Treat Metastatic Colorectal Cancer
Conditions: Colorectal Cancer;   Metastatic Colorectal Cancer
Interventions: Drug: 5-FU;   Drug: LV;   Drug: ziv-aflibercept;   Drug: mFOLFOX6
3 Recruiting AMP-224, a PD-1 Inhibitor, in Combination With Stereotactic Body Radiation Therapy in People With Metastatic Colorectal Cancer
Conditions: Colorectal Cancer;   Colorectal Neoplasms;   Colorectal Carcinoma
Interventions: Drug: AMP-224;   Radiation: Stereotactic Body Radiation Therapy(SBRT);   Drug: Cyclophosphamide
4 Recruiting Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases
Condition: Colorectal Cancer
Interventions: Drug: Oxaliplatin;   Drug: Folinic Acid;   Drug: 5-FU;   Drug: Irinotecan;   Drug: Bevacizumab;   Drug: Cetuximab
5 Recruiting Study of Gemcitabine in Combination With Pemetrexed Long Term Infusion in the Treatment of Pretreated Metastatic Colorectal Cancer Patients
Condition: Metastatic Colorectal Cancer Patients
Intervention: Drug: Gemcitabine + Pemetrexed
6 Active, not recruiting
Has Results
ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
Condition: Metastatic Colorectal Cancer
Interventions: Drug: Cetuximab;   Drug: Panitumumab
7 Recruiting Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Endometrial Cancer;   Solid Tumors
Interventions: Drug: STM 434;   Drug: Liposomal doxorubicin
8 Recruiting Phase II Study of Up-front Chemotherapy and Neo-adjuvant Short-course Radiotherapy for Resectable Rectal Carcinoma (COLORE)
Condition: Resectable Rectal Carcinoma
Interventions: Drug: FOLFOX4;   Radiation: Tomotherapy;   Procedure: TME (Total Mesorectal Excision)

Indicates status has not been verified in more than two years